Humanin (24-amino acid mitochondrial-derived peptide)
First characterized mitochondrial-derived peptide
At a glance
What it is: First characterized mitochondrial-derived peptide.
Primary research applications:
- Research tool for mitochondrial and neurodegeneration biology
- Claimed: neuroprotection and metabolic benefits
Editorial summary: Humanin is an important research peptide with substantial preclinical evidence for neuroprotection and metabolic effects. Human clinical trials are essentially absent; the signal is biological significance, not clinical validation.
What is Humanin?
Humanin was identified in 2001 as the first known mitochondrial-derived peptide, initially found through its ability to protect neurons from Alzheimer's-related apoptosis. Circulating levels decline with age.[1]
Mechanism of action
Binds a cell-surface receptor complex (FPRL1/WSX-1/gp130) to signal through STAT3 and protect cells from apoptosis. Also has effects on insulin sensitivity and mitochondrial function.
What the research shows
The peer-reviewed literature on Humanin is summarized below across two tiers: human research (the highest standard), and preclinical / emerging research (animal models and early-stage human work).
Claims and the evidence behind them
This table summarizes commonly discussed claims and how the published evidence weighs in. The aim is clarity — supported claims, claims that look promising but need more data, and claims that outrun the science.
| Claim | What the evidence shows | Verdict |
|---|---|---|
| Is neuroprotective | Consistent in rodent models | Plausible |
| Improves human cognition or metabolic health when supplemented | No human trial data | Preliminary |
| Is well-established as a longevity intervention | No human longevity data | Unsupported |
Reported user experiences
How the research describes administration
Experimental; no clinical protocol.
Editorial note
Administration details above describe how the peptide is given in published studies. We summarize this for educational completeness — these descriptions are not protocols, dosing recommendations, or instructions for personal use. Decisions about treatment require an appropriately licensed clinician.
Safety considerations and open questions
The takeaway
Important biological discovery with suggestive preclinical data. Not yet a clinical tool. Claims about supplementing humanin for longevity outrun the evidence.
Frequently asked questions
Is humanin the same as MOTS-c?
Both are mitochondrial-derived peptides (encoded in mitochondrial DNA) but they're different molecules with different targets and effects.
Can I buy humanin?
It is available as a research reagent. There is no validated clinical form.
References
- Hashimoto Y, et al. A rescue factor abolishing neuronal cell death by a wide spectrum of familial Alzheimer's disease genes and Abeta. Proc Natl Acad Sci USA. 2001;98(11):6336-41. https://pubmed.ncbi.nlm.nih.gov/11371646/
- Yen K, et al. The mitochondrial derived peptide humanin is a regulator of lifespan and healthspan. Aging. 2020;12(12):11185-11199. https://pubmed.ncbi.nlm.nih.gov/32575074/